The death of Oliver Robinson, 34, in November 2023 has ignited a significant debate surrounding the regulation of private cannabis clinics in the UK. Following an inquest that concluded his prescription for medicinal cannabis may have contributed to his demise, Robinson’s family is advocating for tighter controls to prevent similar tragedies.
The Inquest Findings
In January 2026, coroner Catherine McKenna released startling findings regarding Oliver Robinson’s treatment. The inquest revealed that his prescription for medicinal cannabis, initially obtained from Curaleaf Clinic in May 2022, was deemed an “obstacle” to receiving adequate psychiatric and addiction care. This ruling marks a notable precedent in the ongoing discourse about the safety and efficacy of medicinal cannabis, particularly for individuals with serious mental health issues.
Robinson’s family believes that the cannabis prescription ultimately worsened his condition. “If things do not change he is not going to be the last,” stated his brother, Alexander Robinson, reflecting a deep concern for others who might find themselves in similar predicaments.
The Rise of Medicinal Cannabis in the UK
The legalisation of medicinal cannabis in the UK in 2018 was a watershed moment, primarily driven by the case of a young boy with severe epilepsy. Although the NHS typically prescribes a limited number of licensed cannabis-based medicinal products (CBMPs) for conditions such as epilepsy and multiple sclerosis, the private sector has seen a surge in unlicensed prescriptions. In 2024, over 659,000 unlicensed cannabis products were prescribed privately, significantly increasing from the previous year’s 282,920.
This rapid growth raises concerns about the lack of stringent oversight and the potential risks associated with prescribing cannabis to vulnerable individuals. According to the Care Quality Commission (CQC), many products dispensed by private clinics have not undergone rigorous evaluation by the medicines regulator, raising questions about their safety and efficacy.
A Call for Reform: “Oliver’s Law”
In the wake of the inquest, Alexander Robinson is spearheading a campaign dubbed “Oliver’s Law,” which aims to implement several crucial reforms. These proposals include prohibiting cannabis prescriptions for patients with serious mental illnesses, mandatory consultations with NHS mental health teams, and face-to-face assessments rather than remote consultations for complex cases. Additionally, the campaign calls for increased scrutiny by the CQC through routine audits and public disclosure of prescribing practices.
Dr Pavan Chahl, a psychiatrist who testified during the inquest, highlighted that under current guidelines, prescribing medicinal cannabis to individuals with a history of severe psychiatric disorders is ill-advised due to insufficient evidence supporting its efficacy for treating depression. He emphasised that, given the potential for cannabis to exacerbate mental health conditions, Oliver Robinson should never have received such a prescription.
The Worsening Mental Health Crisis
Oliver Robinson’s struggle with mental health was marked by long-term issues, including depression and addiction, exacerbated by a series of personal setbacks. His tragic journey illustrates the complexities of managing mental health conditions and the role that treatment choices can play in a patient’s overall well-being. After his initial treatment at the Priory, where he was diagnosed with recurrent depressive disorder, he returned to cannabis use, believing it provided relief.
However, as his mental health deteriorated, his behaviour became increasingly erratic and violent, resulting in significant familial distress. The escalation of his condition culminated in tragic circumstances, as his family received alarming warnings about his intentions prior to his death.
Why it Matters
The case of Oliver Robinson serves as a crucial reminder of the urgent need for comprehensive regulation of cannabis prescriptions, especially within the private healthcare sector. As the UK navigates the complexities of medicinal cannabis, the lessons learned from this tragic incident underscore the imperative to prioritise patient safety over expedient treatment options. Strengthening regulatory frameworks could not only protect vulnerable individuals but also ensure that the burgeoning industry operates within safe and ethical boundaries, ultimately fostering a more responsible approach to mental health care in the UK.
